• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 15.85
  • VXN 20.63
  • VXO 18.01
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)

Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

GPRO (GoPro Inc.)
Last Trade 7.2 Dividend/Share 0 PE Ratio -15
Date May 24-2019 Dividend Yield 0.000 Return on Assets -9.04
Change 0.05 ExDividend Date 0 Return on Capital null
Bid 0 Latest EPS -0.78 Price/Sale 0.925
Ask 0 LatestEPS Date 2018-12-31 Price to Book 5.54
Volume 115068 EPS ttm -0.480 Institutional % 51.8
Avg Volume 5.39M Shares Outstanding 153.76M Insider % null
Open 7.2 Float 149.43M Short Ratio null
Prev Close 7.15 Return On Equity -28.86 5 Year Change % -0.770
High 7.265 Consensus EPS -0.18 2 Year Change % -0.157
Low 7.12 No. of Estimate 2.000 1 Year Change % 0.300
52 Week High 7.645 EPS Surprise $ null YTD Change % 0.651
52 Week Low 4 EPS Surprise Percent 0 6 Month Change % 0.361
52 Week Change 30.713 EBITDA 0M 3 Month Change % 0.139
50 Day MA 6.5624 Revenue 0M 1 Month Change % 0.137
200 Day MA Gross Profit 0M 5 Day Change % 0.017
Market Cap 1099.35M Cash 0M 30 Day Change % 0.067
Beta 0.502358 Debt 0M Stock Exchange Nasdaq Global Select
Sector Technology Revenue Per Share 0 Short Interest 0
Short Date 0 Revenue Per Employee 0 Short Ratio null
Data courtesy of IEX
Company Profile

Gen-Probe Incorporated engages in the development, manufacture, and marketing of nucleic acid tests used primarily to diagnose human diseases and screen donated human blood in North America and internationally. The company markets a portfolio of products to detect infectious microorganisms, including those causing sexually transmitted diseases, tuberculosis, strep throat, and other infections. Its primarily product line includes APTIMA Combo 2 assay, APTIMA CT, APTIMA GC assays, and PACE family of assays to detect chlamydia and gonorrhea; APTIMA Trichomonas ASRs to detect trichomonas; APTIMA HPV assay to detect 14 sub-types of high-risk HPV associated with cervical cancer; and AccuProbe Group B Streptococcus (GBS) assay to detect GBS from culture. The company?s product line also include APTIMA HIV-1 assay to detect RNA from HIV-1, the virus that causes AIDS; APTIMA HCV assay to detect RNA from the hepatitis C virus; and ASRs for quantitative HCV testing to quantify HCV viral load. It also offers Pro-Flu+, Pro-Flu ST, ProGastro Cd, AMPLIFIED MTD, and GAS Direct for various respiratory infectious diseases; LIFECODES HLA DNA typing kits and LIFECODES LifeScreen antibody screening kits in the transplant diagnostics field; Procleix HIV-1/HCV assay, Procleix Ultrio assay, Procleix Ultrio Plus assay, and Procleix WNV assay for the blood donor screening market; and TIGRIS and Direct Tube Sampling instrument systems to develop instrumentation. In addition, the company?s developing products include PANTHER, an automated testing instrument. Further, the company offers PROGENSA PCA3 and PCA3 ASRs to detect the PCA3 gene. The company?s customers include reference laboratories, public health institutions, and hospitals. It has a collaboration agreement with Novartis Vaccines and Diagnostics, Inc. for the research, development, and manufacturing of its blood screening products. The company was founded in 1983 and is headquartered in San Diego, California.